NEW YORK, Sept. 10-The chemical genomics company NeoGenesis has successfully identified lead compounds for Mitsubishi Pharma and will continue to develop a small molecule for its Japanese partner, the company said today.
This research builds upon a deal struck in August 2001, whereby NeoGenesis agreed to screen compounds and identify potential drugs for cardiovascular disease targets supplied by Mitsubishi.
NeoGenesis CEO Satish Jindel said that this research program was challenging, and that no small molecules had previously been identified as strong drug candidates for this target.
The company will now develop the compound through preclinical stages, he said. In return, NeoGenesis received an undisclosed milestone payment from Mitsubishi.
NeoGenesis is privately held, and based in